pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 1·1 min read
save

New No Surprises Act arbitration rule may increase provider disputes, critics say

Jun 1, 2026·read at STAT ↗RegulatoryNegative

The administration released a final rule on Thursday that tweaks the No Surprises Act arbitration process. The changes are meant to improve communication between insurers and providers and give Medicare greater visibility into their negotiations.

The rule also seeks to limit arbitration to truly eligible disputes and prevent it from being used as a catch‑all solution.

Despite the revisions, health insurers, providers and consumer advocates warn that the rule does not address the underlying provider gaming that has produced millions in windfalls, and could actually increase the volume of disputes.

Jennifer Jones, senior director of legislative and regulatory affairs at Blue Cross Blue Shield, said the rule makes meaningful progress but called for additional steps to curb the incentives driving overuse of arbitration.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes”

read at STAT ↗
512 words · retrieved Jun 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7
drugs
Obesity
topics
ObesityOncology

related stories

  • Jun 18STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims dataSTAT
  • Jun 18STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims dataSTAT
  • May 12Second Clinical Scenario - Progressive Disease Despite Hematocrit Controlonclive
  • May 13U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changesSTAT
  • May 13The ‘velocity of obesity’ aims to show which nations are slowing an epidemicSTAT